

# Activation of hypoxia-inducible factor-1 $\alpha$ (Hif-1 $\alpha$ ) delays inflammation resolution by reducing neutrophil apoptosis and reverse migration in a zebrafish inflammation model

Philip M. Elks,<sup>1,2</sup> Fredericus J. van Eeden,<sup>1,3</sup> Giles Dixon,<sup>1</sup> Xingang Wang,<sup>4</sup> Constantino Carlos Reyes-Aldasoro,<sup>5</sup> Philip W. Ingham,<sup>4</sup> Moira K. B. Whyte,<sup>1,2</sup> Sarah R. Walmsley,<sup>2</sup> and Stephen A. Renshaw<sup>1,2</sup>

<sup>1</sup>MRC Centre for Developmental and Biomedical Genetics, <sup>2</sup>Academic Unit of Respiratory Medicine, Department of Infection and Immunity, and <sup>3</sup>Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom; <sup>4</sup>Institute of Molecular and Cellular Biology, Proteos, Singapore; and <sup>5</sup>Cancer Research UK Tumour Microcirculation Group, Department of Oncology, University of Sheffield, Sheffield, United Kingdom

The oxygen-sensing transcription factor hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) plays a critical role in the regulation of myeloid cell function. The mechanisms of regulation are not well understood, nor are the phenotypic consequences of HIF modulation in the context of neutrophilic inflammation. Species conservation across higher metazoans enables the use of the genetically tractable and transparent zebrafish (*Danio rerio*) embryo to study in vivo resolution of the inflammatory response. Using both a pharmacologic ap-

proach known to lead to stabilization of HIF-1 $\alpha$ , and selective genetic manipulation of zebrafish HIF-1 $\alpha$  homologs, we sought to determine the roles of HIF-1 $\alpha$  in inflammation resolution. Both approaches reveal that activated Hif-1 $\alpha$  delays resolution of inflammation after tail transection in zebrafish larvae. This delay can be replicated by neutrophil-specific Hif activation and is a consequence of both reduced neutrophil apoptosis and increased retention of neutrophils at the site of tissue injury. Hif-activated neutro-

phils continue to patrol the injury site during the resolution phase, when neutrophils would normally migrate away. Site-directed mutagenesis of Hif in vivo reveals that hydroxylation of Hif-1 $\alpha$  by prolyl hydroxylases critically regulates the Hif pathway in zebrafish neutrophils. Our data demonstrate that Hif-1 $\alpha$  regulates neutrophil function in complex ways during inflammation resolution in vivo. (*Blood*. 2011;118(3):712-722)

## Introduction

Neutrophilic inflammation is of fundamental importance in the innate immune response to bacterial and fungal infection in vertebrates, and it can be initiated by sterile tissue injury. Irrespective of its etiology, inflammation must resolve in a timely manner to avoid damage to surrounding tissues.<sup>1</sup> Persisting, noninfectious inflammation is the hallmark of inflammatory diseases, a major cause of morbidity and mortality in the developed world. The resolution phase of inflammation is critical to the restoration of normal tissue function after an inflammatory response, and thus has a central role in determining the outcome of inflammation.<sup>2</sup> Despite the central place of failed resolution in the pathogenesis of inflammatory disease, much remains to be known about the cellular and molecular events involved.

Although neutrophil apoptosis, and subsequent uptake and removal by macrophages (efferocytosis), is well documented as a disposal route for inflammatory neutrophils,<sup>3-5</sup> there is emerging evidence that other mechanisms also may contribute to certain types of inflammation resolution. In the lung, some neutrophils are lost into the airways and expectorated,<sup>6</sup> and in rheumatoid arthritis, neutrophils may leave the inflammatory site while still alive and re-enter the circulation.<sup>7</sup> Neutrophils also can be removed by migration through tissues away from the infection site; a process termed retrograde chemotaxis, or reverse migration.<sup>8-10</sup> This process is most widely characterized in the zebrafish (*Danio rerio*) embryo and is less well studied in mammalian systems.

Each of these aspects of inflammation resolution may contribute to the removal of neutrophils and be influenced by a range of extracellular signals encountered by neutrophils at the site of inflammation, including cytokines,<sup>11,12</sup> bacterial products,<sup>12,13</sup> and low oxygen tensions.<sup>14-16</sup> Physiologic hypoxia is important because it induces both extended survival and preserved activity in neutrophils. Hypoxia exerts its effects in part through stabilization of hypoxia-inducible factor (HIF), with activation of the HIF pathway in murine myeloid cells by myeloid-specific *Vhl* knockout leading to increased myeloid cell recruitment.<sup>17</sup> HIF signaling can be activated in normoxia by exposure of myeloid cells to bacterial products, demonstrating the fundamental importance of this pathway to immune cell function.<sup>18</sup> The effects of HIF-1 $\alpha$  activation and silencing on resolution of neutrophilic inflammation have yet to be fully characterized, especially in an in vivo setting.

Three HIF- $\alpha$  isoforms have been identified in humans, of which HIF-1 $\alpha$  is a key regulator of neutrophil function and life span.<sup>17-19</sup> HIF-1 $\alpha$  stability is regulated by a group of oxygen-sensitive enzymes: prolyl hydroxylases (PHDs) and factor-inhibiting HIF (FIH). Oxygen-dependent PHD activity leads to degradation of HIF-1 $\alpha$  via a ubiquitin ligase complex coordinated by the von Hippel Lindau (VHL) protein (pVHL).<sup>20-22</sup> In contrast, hypoxia reduces PHD activity, stabilizing HIF-1 $\alpha$ , which joins a nuclear complex with the constitutively expressed HIF- $\beta$  (or aryl hydrocarbon nuclear translocator [ARNT]) and transduces the cellular

Submitted December 15, 2010; accepted April 9, 2011. Prepublished online as *Blood* First Edition paper, May 10, 2011; DOI 10.1182/blood-2010-12-324186.

The online version of the article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2011 by The American Society of Hematology

response.<sup>22-24</sup> The HIF pathway can be manipulated pharmacologically using nonspecific inhibitors of PHD enzymes, for example, dimethylxaloylglycine (DMOG), leading to stabilization of HIF-1 $\alpha$  in vitro.<sup>25</sup> Such pan-hydroxylase inhibitors lack specificity, however, with potential widespread effects on cellular physiology.

Here, using a transgenic zebrafish line expressing a neutrophil-specific reporter gene,<sup>26</sup> we investigate the effects of pharmaceutical and genetic manipulation of Hif-1 $\alpha$  activity on neutrophil behavior in vivo. We show for the first time that the resolution of neutrophilic inflammation in vivo is delayed after DMOG treatment in a whole organism model. We show this delay in resolution is a consequence both of a decrease in neutrophil apoptosis and of increased retention of neutrophils at the site of inflammation. Furthermore, using dominant-active and dominant-negative variants of the 2 zebrafish homologs of HIF-1 $\alpha$  (Hif-1 $\alpha$ a and Hif-1 $\alpha$ b), we show timely resolution of neutrophilic inflammation is dependent on prolyl hydroxylation of Hif-1 $\alpha$ b, demonstrating the importance of the HIF pathway in determining the outcome of inflammation in vivo.

## Methods

### Fish husbandry

Two neutrophil-specific fluorescent zebrafish lines were used: *Tg(mpx:GFP)i114*<sup>26</sup> and *Tg(lyz:GAL4.VP16)i252;Tg(UAS-Elb:Kaede)s1999t*, subsequently termed *mpx:GFP* and *lyz:Kaede*, respectively. Zebrafish strains were maintained according to standard protocols.<sup>27</sup> Adult fish were maintained on a 14:10-hour light/dark cycle at 28°C in UK Home Office approved facilities in the MRC Centre for Developmental and Biomedical Genetics aquaria at the University of Sheffield.

### Inflammation assay

Inflammatory responses were elicited in zebrafish embryos by tail transection as described previously.<sup>26</sup> Embryos were anesthetized at 2 or 3 days postfertilization (dpf) by immersion in 0.168 mg/mL tricaine (Sigma-Aldrich), and transection of the tail was performed with a scalpel blade briefly immersed in the chemoattractant f-Met-Leu-Phe (100nM; Sigma-Aldrich). Treatment with 100 $\mu$ M DMOG (or DMSO vehicle control) was performed by immersion at 4 hours postinjury (hpi) or for recruitment assays for 2 hours before injury. Neutrophils were counted at the site of transection at 6, 24, and 48 hpi using a fluorescent dissecting stereomicroscope (Leica) as described previously.<sup>26</sup> Where possible, counting was performed blind to experimental conditions.

### Apoptosis assays

Rates of apoptosis were assessed blindly by TUNEL/Tyramide Signal Amplification (TSA) or by anti-active caspase-3/TSA staining, as described previously.<sup>28,29</sup>

*Mpx:GFP* embryos were injured at 3 dpf (2 dpf for RNA-injected embryos) and 10 dpf. Embryos were treated with DMSO/DMOG at 4 hpi and fixed at 12 hpi in 4% paraformaldehyde. TUNEL (ApopTag Red; Millipore Corporation) staining labeled apoptotic cells with red fluorescence, and TSA (TSAplus kit; Fluorescence Systems, PerkinElmer Life and Analytical Sciences) staining labeled neutrophils with fluorescein green fluorescence. Anti-active caspase-3 (R&D Systems) staining with a fluorescein secondary antibody (Alexa Fluor 488, goat anti-rabbit IgG; Invitrogen) gave green fluorescence. Neutrophils were labeled with red fluorescence using cyanine-3 TSA (TSAplus kit; Fluorescence Systems, PerkinElmer Life and Analytical Sciences).

Neutrophils in the tail transection region were imaged on an UltraVIEWVoX spinning-disk confocal microscope (PerkinElmer Life and Analytical Sciences), and apoptosis was assessed by the percentage of TSA-positive neutrophils labeled with TUNEL or active caspase-3.

### Development of a stable *Tg(lyz:GAL4.VP16)i252* transgenic line

The Tol2kit multisite Gateway-based transposon system was used to make a transgenic construct from which a stable line was raised.<sup>30</sup> Eleven kilobases of the lysosyme C promoter (kindly provided by Phil Crosier, School of Medical Sciences, The University of Auckland, New Zealand),<sup>10</sup> was cloned into the p5E-MCS entry vector (Xho-I and Sma-I sites). An LR Clonase II Plus enzyme (Invitrogen) Gateway reaction was performed with the resulting p5E-*lyz* along with pME-Gal4VP16, p3E-polyA inserted into pDestTol2pA2 to produce *lyz:Gal4VP16* construct. This construct was co-injected with tol2-transposase RNA into zebrafish 1-cell-stage embryos to create the *Tg(lyz:GAL4.VP16)i252* transgenic line.

### Photoconversion of neutrophil-specific Kaede protein

Tail transection of *lyz:Kaede* larvae was performed at 2 or 3 dpf as described previously.<sup>26</sup> Embryos were raised to 6 hpi and mounted in 1% low-melting-point agarose (Sigma-Aldrich). An UltraVIEW PhotoKinesis device on an UltraVIEWVoX spinning disk confocal microscope (PerkinElmer Life and Analytical Sciences) was used to photoconvert the Kaede-labeled cells using 120 pulses of the 405 nm laser at 40% laser power (optimized in previous experiments; data not shown). Embryos were transferred to an Eclipse TE2000-U inverted compound fluorescence microscope (Nikon), where a 1394 ORCA-ERA camera (Hamamatsu Photonics Inc) was used to capture a time-lapse series. Cells fluorescing in the red channel were then tracked over a 3.5-hour period.

### Neutrophil tracking

Tracking analysis was performed in Volocity 5 (Improvision; PerkinElmer Life and Analytical Sciences), using the intensity of fluorescence to identify individual labeled neutrophils over time.

### Morpholino knockdown of *arnt-1*

The *arnt-1* morpholino (Genetools) was used as reported previously.<sup>31</sup> A standard control morpholino (Genetools) was used as a negative control.

### hif-1 $\alpha$ cloning

Zebrafish 2 dpf RNA purified using TRIzol (Invitrogen) was used for RT-PCR reaction cloning of zebrafish *hif-1 $\alpha$ a* and *hif-1 $\alpha$ b* (using primers in supplemental Table 1; available on the Blood Web site; see the Supplemental Materials link at the top of the online article) using Pfu fusion polymerase (Finnzymes). These were cloned into TOPOBlunt (Invitrogen) and were subsequently subcloned into pCS2+ (Invitrogen) for RNA synthesis and in situ hybridization expression studies.

Dominant-negative forms of *hif-1 $\alpha$ a* and *hif-1 $\alpha$ b* were generated using primers amplifying DNA corresponding to amino acids 1-330 of human HIF-1 $\alpha$ .<sup>32</sup> Dominant-active forms of *hif-1 $\alpha$ a* and *hif-1 $\alpha$ b* were generated by successive rounds of site-directed mutagenesis.<sup>20,33,34</sup> In each round, one of the hydroxylation sites was mutated into nonhydroxylatable amino acids as described previously in human HIF-1 $\alpha$ .<sup>20,33,34</sup>

Dominant-negative and dominant-active RNAs were transcribed (mMessageMachine; Ambion, Invitrogen) and microinjected into zebrafish embryos at the 1-cell stage as described previously.<sup>27,35</sup> A *phd-3* in situ hybridization was performed to assess the function of dominant hif-1 $\alpha$  variants, using previously described methods.<sup>35,36</sup>

### Development of a stable *Tg(UAS:da-hif-1 $\alpha$ b-IRES-GFP)i218* transgenic line

Dominant-active *hif-1 $\alpha$ b* was cloned into the middle entry pME-MCS. An LR Clonase (Invitrogen) Gateway reaction was performed with p5E-UAS, pME-*da-hif-1 $\alpha$ b* and p3E-IRES-EGFPpA inserted into pDestTol2pA2. The resulting plasmid was microinjected with tol2-transposase RNA into 1-cell-stage embryos. Internal ribosome entry site-green fluorescent protein (IRES-GFP) expression was weak, so founders were screened by heart marker GFP expression. The resulting *Tg(UAS:da-hif-1 $\alpha$ b-IRES-GFP)i218* is subsequently referred to as *UAS:da-hif-1 $\alpha$ b*.

Functional Hif expression was tested in *UAS:da-hif-1 $\alpha$ b*, by injection with a *cmv:Gal4VP16-IRES-nlsEGFP* construct, made from the *tol2kit* as described previously.<sup>30</sup> Injected larvae were screened for expression of *nlsEGFP* at 3 dpf and a *phd-3* in situ hybridization was performed to assess levels of *Hif-1 $\alpha$*  signaling. To investigate the effects of *da-hif-1 $\alpha$ b* expression on the resolution of neutrophilic inflammation, *UAS:da-hif-1 $\alpha$ b* were crossed to *Tg(lyz:Gal4)i252* fish to generate double transgenic embryos identified by the presence of GFP heart marker and mCherry-labeled leukocytes.

### Statistical analysis

Data were analyzed (Prism 5.0; GraphPad Software) using unpaired, 2-tailed *t* tests for comparisons between 2 groups and 1-way ANOVA (with Bonferroni posttest adjustment) for other data.

## Results

### DMOG treatment delays resolution of inflammation

After tail transection in *mpx:GFP* embryos at 3 dpf, neutrophil numbers can be assessed by counting fluorescent cells, visible in association with the site of injury. Neutrophil numbers act as a measure of the magnitude of the inflammatory response because they are its main cellular component. Neutrophils are recruited early, with numbers peaking at ~ 6 hours,<sup>26</sup> followed by spontaneous resolution of this neutrophilic inflammation over 24 hours (Figure 1A). Macrophages are recruited later and persist longer.<sup>37</sup>

Because of the known effects of the pan-hydroxylase inhibitor DMOG on neutrophil apoptosis, we hypothesized that DMOG would delay inflammation resolution in the zebrafish tailfin model. Agents delaying neutrophil apoptosis have been shown to delay inflammation resolution in this model when added once neutrophils have been recruited.<sup>28</sup> We therefore added 100  $\mu$ M DMOG at 4 hpi and then observed the effects on inflammation resolution. Treatment with DMOG caused a significant increase in neutrophil numbers at 24 hpi (Figure 1B-D) compared with DMSO-treated controls (Figure 1A,C-D) from the same clutch of embryos, but numbers had decreased to basal levels by 48 hpi, despite persistence of Hif signaling at 48 hpi, as assessed by in situ hybridization expression of the target gene *phd-3* (supplemental Figure 1A). There were no additional effects of DMOG on neutrophil distribution throughout the embryo (Figure 1E), nor any increase in total neutrophil number (supplemental Figure 1B). DMOG dose and timing of administration were assessed and found to be optimal (supplemental Figure 1C-D).

Recruitment of neutrophils was assessed at 6 hpi and was unchanged by DMOG treatment (Figure 1F), confirming that the differences seen in percentage change in neutrophil number from 6 to 24 hours (a measure of inflammation resolution) in DMOG-treated embryos is independent of effects on neutrophil recruitment (Figure 1G).

Neutrophil counts do not take account of changes in the migration behavior of neutrophils, which may be affected by hydroxylase inhibition. We therefore assessed the speed and meandering of neutrophil migration toward the site of tail transection by in vivo tracking of *mpx:GFP* neutrophils over 1 hour during the recruitment phase using 3D time-lapse videomicroscopy (Figure 1H). This tracking technique was sensitive enough to detect changes in neutrophil recruitment after treatment with the chemoattractant *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP; supplemental Figure 2A-B). After DMOG treatment, however, no significant difference in neutrophil speed (Figure 1I) or meandering

index (Figure 1J) was observed compared with vehicle-only controls during the recruitment phase.

### DMOG treatment decreases neutrophil apoptosis and retains neutrophils at the inflammatory site


DMOG treatment increased the number of neutrophils at the site of tail transection at 24 hpi, but the mechanisms behind this delay in resolution remained unknown. Neutrophils were never seen to leave the zebrafish body through the wound margin or elsewhere, and it is reasonable to conclude that loss of neutrophils from the larva is not important in this model. We therefore assessed the effects of DMOG both on levels of neutrophil apoptosis at the transection site, and on migration of neutrophils away from it.

Neutrophil apoptosis was quantified using TUNEL staining to identify apoptotic cells, in combination with a fluorescent histochemical stain to identify neutrophils, as reported previously.<sup>28,29,38</sup> Postmortem TSA staining was used in preference to GFP imaging, because we have previously shown GFP fluorescence is lost during neutrophil apoptosis.<sup>28</sup> In DMOG-treated larvae, there was a significant decrease in apoptotic neutrophils at the transection site compared with that of DMSO-treated larvae at 3 dpf (Figure 1K). The rates of apoptosis seen are comparable to those in other studies of zebrafish neutrophil apoptosis,<sup>28</sup> and to published rates of detectable apoptosis in other models.<sup>39</sup> Because levels of detectable neutrophil apoptosis are low, these events are scarce in fixed embryos at a single time point, presumably reflecting the short life span of an apoptotic neutrophil in vivo. Therefore, this experimental result was confirmed at 10 dpf where numbers of neutrophils are higher using both TUNEL and anti-active caspase-3 staining (supplemental Figure 3A-B).


To investigate the migration of neutrophils away from the transection site, *lyz:Kaede* transgenic fish were used. *lyz:Kaede* fish use the lysozyme C promoter to drive GAL4, which drives expression of Kaede, a photoconvertible protein that fluoresces in the red channel after exposure to 405-nm excitation.<sup>40</sup> This allows individual cells, or cells within a certain area, to be converted from green to red fluorescence and tracked over time. Tailfin transection was performed in *lyz:Kaede* transgenic zebrafish at 3 dpf, and at 6 hpi the neutrophils present at the transection site were photoconverted to red fluorescence and tracked over the next 3.5 hours (Figure 2A). Embryos treated with DMOG had significantly fewer red neutrophils moving away from the injury site than DMSO controls (Figure 2B-D). Not only were more neutrophils in DMSO-treated embryos moving away from the injury site, but they were moving further away than those treated with DMOG (supplemental Figure 4A).

To further investigate neutrophil movement at the injury site after DMOG treatment, a small area of between 5 and 10 neutrophils located at the dorsal side of the midline near the wound was photoconverted at 6 hpi (Figure 3A). It was observed that DMSO-treated neutrophils tended to migrate away from the injury site, whereas DMOG-treated neutrophils favored migration along the injury edge (Figure 3B). This was independent of measurements of speed and meandering, which remained unchanged after treatment (Figure 3C). Over 3.5 hours of tracking, neutrophils migrated out of the photoconverted region at the same rate in both DMSO- and DMOG-treated individuals (Figure 3D). Fewer neutrophils migrate away from the injury site in DMOG-treated individuals than in DMSO controls (Figure 3E), whereas more neutrophils in DMOG-treated embryos moved down the injury site ventral of the photoconverted region (Figure 3F). This is consistent with





**Figure 1. DMOG delays resolution of neutrophilic inflammation.** (A-B) Fluorescent neutrophil numbers in the *mpx:GFP* line were counted at 6, 24, and 48 hpi in anesthetized embryos. Six hpi is the time point of maximal neutrophil recruitment. By 24 hpi, neutrophilic inflammation has resolved in wild-type embryos. At 4 hpi, fish were treated with 100  $\mu$ M DMOG (B) or with DMSO as vehicle control (A). Data shown are individual embryos for each line,  $n = 18$  performed as 3 independent experiments. (C) Fluorescence photomicrographs of 8 zebrafish tails from control (DMSO; top panel) and DMOG-treated (bottom panel) larvae. Imaged at 24 hpi, original magnification  $\times 2$  on a TE2000U inverted microscope (Nikon) at constant exposure. (D-E) Overlaid fluorescence and brightfield photomicrographs of injured 3 dpf embryos at 6 and 24 hpi (D) or uninjured 3 and 4 dpf embryos (E) after treatment at 3 dpf with DMSO and DMOG. Imaged at original magnification  $\times 2$  on a TE2000U inverted microscope (Nikon) at constant exposure. (F) The 6-hpi time point neutrophil counts, in DMSO- and DMOG-treated zebrafish embryos. Data shown are mean  $\pm$  SEM,  $n = 18$  performed as 3 independent experiments. (G) Resolution of the cellular component of inflammation is decreased in DMOG-treated embryos, expressed as percentage of change in neutrophil number between 6 and 24 hpi. Data shown are mean  $\pm$  SEM,  $n = 18$  performed as 3 independent experiments.  $P$  values were calculated using 1-way ANOVA and Bonferroni multiple comparison test, \* $P < .05$ , \*\* $P < .01$ , and \*\*\* $P < .001$ . (H) Photomicrograph of a typical tracking experiment, with arrows indicating the path of neutrophil movement over a 1-hour time lapse during the recruitment phase of inflammation (1-2 hpi). No difference was observed in the speed of neutrophil migration (I) or meandering index (displacement/path length; J) in DMOG-treated larvae compared with DMSO controls. Data shown are mean  $\pm$  SEM,  $n = 18$  performed as 3 independent experiments. (K) TUNEL and TSA colocalization shows the percentage of neutrophils at the injury site undergoing apoptosis. Data shown are mean  $\pm$  SEM,  $n = 3$  performed as independent experiments each containing 35 to 40 embryos/treatment group.



**Figure 2. DMOG retains neutrophils in the region of tissue injury.** (A) Photomicrographs of a 3-dpf photoconverted, DMSO-treated, *lyz:Kaede* embryo at 0 hours postconversion (hpc). The white dashed line indicates the border of the site of transection area. The cells to the right of the line were photoconverted, leaving them with red fluorescence rather than green. The bottom fluorescent panel shows the area of interest where neutrophils migrated away from the injury site shown in a subsequent figure (D). (B) Photomicrographs of the same embryo as in panel A at 0 and 3.5 hpc. The red channel only is shown, as a binary image. Between 0 and 3.5 hpc, photoconverted cells have migrated away from the site of transection. (C) Photomicrographs of a DMOG-treated embryo at 0 and 3.5 hpc converted into black and white. Fewer photoconverted leukocytes have migrated away from the site of transection. (D) Plot showing the number of photoconverted leukocytes leaving the area of transection over 3.5 hpc in DMSO- and DMOG-treated embryos. Data shown are mean  $\pm$  SEM,  $n = 9$  performed as 2 independent experiments. Line of best fit shown is calculated by linear regression.  $P$  value shown is for the difference between the 2 slopes.

DMOG-treated neutrophils patrolling the injury site, rather than moving away.

#### DMOG-induced delay in resolution is blocked by *arnt-1* morpholino and by dominant-negative *hif-1 $\alpha$ b*

Given the potential for nonspecific effects of competitive hydroxylase inhibition by DMOG and the lack of selective inhibitors of individual PHD enzymes, we sought to investigate the HIF-1 $\alpha$  dependence of hydroxylase inhibition. ARNT-1 (or HIF-1 $\beta$ ) is a crucial binding partner of HIF-1 $\alpha$ , and *arnt-1* morpholino<sup>31</sup> will block Hif signaling. In the morpholino experiments, tail transection was performed at 2 dpf, to increase the likelihood that the morpholino would remain active during the experiment. The 2-dpf tail transection model retains the same features as the 3-dpf model used in other studies,<sup>26,28,41</sup> and was used for all morpholino and RNA injection experiments described here. In control morpholino-injected larvae, DMOG increased neutrophil numbers at 24 hpi. Treatment with DMOG after *arnt-1* morpholino injection, how-

ever, caused no significant increase in neutrophil numbers at 24 hpi (Figure 4A), supporting the Hif dependence of the DMOG effect.

A truncated form of human HIF-1 $\alpha$  has been shown previously to block HIF-1 $\alpha$  signaling in cell culture.<sup>32</sup> We generated analogous constructs for the zebrafish homologs, *hif-1 $\alpha$ a* and *hif-1 $\alpha$ b*. These were expressed in all cells of the embryo by RNA injection at the 1-cell stage. We showed dominant-negative *hif-1 $\alpha$ a* was able to block activation of the HIF pathway by DMOG as late as 56 hpf, indicated by a decrease in *phd-3* expression (supplemental Figure 5).<sup>42</sup> Dominant-negative *hif-1 $\alpha$ a* abrogated the DMOG-induced increase in neutrophil numbers at the transection site at 24 hpi (Figure 4B), with no effect on wholebody neutrophil numbers (Figure 4C). Dominant-negative *hif-1 $\alpha$ b* alone was sufficient to block the DMOG delay in resolution of neutrophilic inflammation (Figure 4B), with *hif-1 $\alpha$ a* having no effect on inflammation (Figure 4B).

TUNEL staining showed that there was no significant difference in levels of neutrophil apoptosis in embryos injected with dominant-negative *hif-1 $\alpha$ a* (Figure 4D).


To investigate the effect on neutrophil retention at the inflammatory site, *lyz:Kaede* embryos were injected with dominant-negative *hif-1 $\alpha$ b* RNA and neutrophils at the inflammatory site were photoconverted. Neutrophil movement away from the wound was investigated at 6 hpi after tail transection at 2 dpf. In phenol red-injected negative control embryos, DMOG treatment caused fewer neutrophils to leave the site of transection (supplemental Figure 4B), as was observed at 3 dpf. However, in embryos injected with dominant-negative *hif-1 $\alpha$ b*, DMOG-treated embryos had similar numbers of neutrophils migrating away from the site of transection as the DMSO-treated individuals (Figure 4E-F). The neutrophils that did move away moved similar distances away from the injury site in treatment groups (supplemental Figure 4C). Therefore, dominant-negative *hif-1 $\alpha$ a* is able to negate the DMOG-induced delay in resolution partially by restoring the normal pattern of neutrophil movement away from the wound edge.

#### Dominant-active *hif-1 $\alpha$ b* delays resolution of neutrophilic inflammation

Dominant-active forms of Hif-1 $\alpha$ a and Hif-1 $\alpha$ b were generated by mutation of conserved proline hydroxylation sites for Phd and the asparagine hydroxylation site for Fih (Figure 5A). In mammalian studies, these mutations render HIF-1 $\alpha$  resistant to hydroxylation by oxygen-sensitive hydroxylases, leading to stabilization of HIF-1 $\alpha$ .<sup>20,33</sup> In zebrafish larvae expressing dominant-active *hif-1 $\alpha$ a* by RNA injection, Hif signaling was up-regulated, shown by increased *phd-3* expression (supplemental Figure 5). In addition, an increase in neutrophil number at 24 hpi was observed in dominant-active *hif-1 $\alpha$ a*/DMSO-treated embryos, with neutrophil numbers comparable to DMOG-treated/mock-injected siblings (Figure 5B). As with dominant-negative *hif-1 $\alpha$ a*, dominant-active *hif-1 $\alpha$ b* alone recapitulated the effects of DMOG on 24 hpi neutrophil numbers present at the transection site (Figure 5B). Neither dominant-active nor -negative *hif-1 $\alpha$ a* had any effect in these assays. In situ hybridization expression of wild-type *hif-1 $\alpha$ a* and *hif-1 $\alpha$ b* showed similar expression patterns, although in general *hif-1 $\alpha$ a* seemed to be expressed at a lower level than *hif-1 $\alpha$ b* (supplemental Figure 6).

Dominant-active *hif-1 $\alpha$ a* injection was associated with increased wholebody neutrophil numbers at 2 dpf (Figure 5C), suggesting activation of Hif signaling might regulate total neutrophil numbers in vivo. Because HIF is activated by infection, this effect might contribute to the increase in neutrophils seen during infections; however, this increase in wholebody neutrophil number did not

**Figure 3. DMOG treatment causes a change in direction of neutrophil movement independent of neutrophil speed and meandering.** (A) Photomicrographs of a 3-dpf photoconverted, DMSO-treated, *lyz:Kaede* embryo at 0 hpc. The white box indicates the area of photoconverted neutrophils. The bottom panel shows the regions to which neutrophils migrated in subsequent panels (D-F). (B) Photomicrographs of examples of DMSO (top panel)– and DMOG (bottom panel)–treated embryos with the tracks of neutrophils over the first 3.5 hpc shown. The dashed line indicates the outline of the embryo. (C) Tracking of neutrophils over the first 3.5 hpc in the resolution phase of inflammation showed no difference in the speed of neutrophil migration (top panel) or meandering index (displacement/path length; bottom panel) in DMOG-treated larvae compared with DMSO controls. (D) Leukocytes leave the photoconversion site at the same rate in DMSO- and DMOG-treated embryos over 3.5 hpc. (E) Number of photoconverted leukocytes moving away from the wound is shown over 3.5 hpc in DMSO- and DMOG-treated embryos. (F) More neutrophils remain and patrol the injury site in DMOG-treated embryos, because a greater number of leukocytes move within the injury region, ventrally away from the patch area. (D-F) Data shown are mean  $\pm$  SEM,  $n = 14$  performed as 3 independent experiments. Line of best fit shown is calculated by linear regression.  $P$  values shown are the differences between the 2 slopes.



cause an increase in neutrophil recruitment to the injury site at 6 hpi (Figure 5D). Like DMOG, dominant-negative and dominant-active forms of *hif-1 $\alpha$*  caused no significant changes in neutrophil speed or meandering index during the recruitment phase (supplemental Figure 2C-D).


TUNEL staining showed that there was a significant decrease in levels of neutrophil apoptosis in embryos injected with dominant-active *hif-1 $\alpha$*  (Figure 5E), similar to that observed in DMOG (Figure 1K). Neutrophil migration away from the injury site was assessed as with *lyz:Kaede*. Fewer neutrophils move out of the injury site in dominant-active *hif-1 $\alpha$* -injected embryos compared with phenol red-injected controls (Figure 5F).

Each hydroxylation site of Hif-1 $\alpha$ b was mutated individually, and RNA was injected into *mpx:GFP* larvae to assess their effects on neutrophil retention at 24 hpi. Mutation of either of the 2 Phd

target proline residues was sufficient to significantly increase the neutrophil numbers at the site of transection at 24 hpi to the same or greater level as DMOG treatment (Figure 5G). Mutation of the Fih target asparagine had no effect on neutrophil numbers at 24 hpi (Figure 5G).

To confirm the effects of Hif activation act within the neutrophil itself, a stable transgenic line expressing dominant-active *hif-1 $\alpha$ b* under the upstream activating sequence (UAS) promoter was generated (*UAS:da-hif-1 $\alpha$ b*). This line was shown to express active Hif when driven by an injected *cmv:GAL4* construct, demonstrated by increased *phd-3* expression (supplemental Figure 7). Dominant-active *hif-1 $\alpha$ b* was expressed in neutrophils by crossing *UAS:da-hif-1 $\alpha$ b* with the *lyz:Gal4* line described above. After tail transection at 3 dpf, neutrophils were counted at 24 hpi using fluorescent TSA. Neutrophil numbers at 24 hpi






**Figure 4. DMOG-induced delay in inflammation resolution is blocked by genetic inhibition of the Hif-1 $\alpha$  pathway.**

(A) The 24 hpi neutrophil counts in the *mpx:GFP* line at 2 dpf after injection with control and *arnt-1* morpholinos. DMSO and DMOG treatment was performed at 4 hpi. Data shown are mean  $\pm$  SEM,  $n = 12$  performed as 2 independent experiments. (B-E) We injected 177 pg of dominant-negative *hif-1 $\alpha$*  RNA into the 1-cell-stage zebrafish *mpx:GFP* embryos, and then neutrophil counts were performed at 24 hpi after tail transection at 2 dpf. (B) Injection of dominant-negative *hif-1 $\alpha$ b* abrogated the increase in neutrophil number at the site of injury at 24 hpi seen with DMOG treatment, whereas embryos injected with phenol red as a negative control, or dominant-negative *hif-1 $\alpha$ a* alone exhibited a significant increase in neutrophil number after DMOG treatment. Data shown are mean  $\pm$  SEM,  $n = 24$  performed as 2 independent experiments.  $P$  values were calculated using 1-way ANOVA and Bonferroni multiple comparison test, where  $P < .05$ ,  $**P < .01$ , and  $***P < .001$ . (C) Injection of dominant-negative *hif-1 $\alpha$*  variants led to no significant difference in total neutrophil number at 2 pf compared with phenol red-injected negative control embryos. Data shown are mean  $\pm$  SEM,  $n = 36$  performed as 3 independent experiments. (D) Injection of dominant-negative *hif-1 $\alpha$*  caused no significant change in percentage of neutrophils at the injury site colabeling with TUNEL stain (12 hpi injured at 2 dpf). Data shown are mean  $\pm$  SEM,  $n = 4$  performed as independent experiments containing 5 to 25 embryos/injection group/repeat. (E-F) Dominant-negative *hif-1 $\alpha$*  can block the increased neutrophil retention at the site of injury caused by DMOG treatment. Embryos were injected with dominant-negative *hif-1 $\alpha$ b*, grown to 3 dpf, and imaged 3.5 hours after photoconversion, with only the red channel shown, as a binary image. (E, left panels) In DMSO-treated larvae, red-labeled neutrophils have migrated away from the site of transection. (E, right panel) In DMOG-treated larvae, red-labeled neutrophils also move away from the site of transection. (F) The number of red (photoconverted) lysozyme C-labeled cells leaving the area of transection at 6 hpi over a time period of 3.5 hpc in DMSO- and DMOG-treated embryos at 2 dpf that were injected at the 1-cell stage with dominant-negative *hif-1 $\alpha$ b*. Data shown are mean  $\pm$  SEM,  $n = 14$  performed as 3 independent experiments. Line of best fit shown is calculated by linear regression.  $P$  value shown is the difference between the 2 slopes.

are elevated in embryos with the heart marker (ie, *da-hif-1 $\alpha$*  positive) compared with heart marker negative siblings (Figure 5H). As with dominant-active *hif-1 $\alpha$*  RNA experiments, levels of apoptosis are significantly reduced in *da-hif-1 $\alpha$*  positive transgenics compared with controls (Figure 5I).

## Discussion

In this study, we investigated the role of the HIF pathway in modulating neutrophilic inflammation in vivo. Although several in



**Figure 5. Dominant-active *hif-1αb* delays resolution of neutrophilic inflammation.** (A) Partial protein alignment showing the conserved hydroxylation sites of Hif-1 $\alpha$ . Dominant-active *hif-1α* has the following nonhydroxylatable mutations: Hif-1 $\alpha$  P402A, P564G, N804A and Hif-1 $\alpha$  P493G, N678A (Hif-1 $\alpha$  lacks the first proline hydroxylation residue). (B-F) Dominant-active forms of *hif-1α* RNA (177 pg) were injected into the 1-cell-stage zebrafish *mpx:GFP* embryos, tailfin transection was performed at 2 dpf, and neutrophils counted at 24 hpi. (B) Dominant-active *hif-1α* caused a significant increase in neutrophil number in the absence of DMOG treatment compared with phenol red-injected negative controls. Dominant-active *hif-1αb* alone was able to recapitulate the DMOG phenotype, whereas dominant-active *hif-1αa* homolog did not. Data shown are mean  $\pm$  SEM,  $n = 24$  performed as 2 independent experiments.  $P$  values were calculated using 1-way ANOVA and Bonferroni multiple comparison test, where  $P < .05$ ,  $**P < .01$ , and  $***P < .001$ . (C) Injection of dominant-active *hif-1α* variants led to a significant increase in total neutrophil numbers at 2 dpf. Data shown are mean  $\pm$  SEM,  $n = 36$  performed as 3 independent experiments. (D) Injection of dominant-active *hif-1α* variants did not alter the recruitment of neutrophils to the injury site after 6 hpi when the tail was transected at 2 dpf. Data shown are mean  $\pm$  SEM,  $n = 24$  performed as 2 independent experiments.  $P$  values were calculated using 1-way ANOVA and Bonferroni multiple comparison test. (E) Injection of dominant-active *hif-1α* led to a significant decrease in percentage of neutrophils at the injury site colabeled with TUNEL apoptosis staining 12 hpi when injured at 2 dpf. Data shown are mean  $\pm$  SEM,  $n = 4$  performed as independent experiments containing 10 to 25 embryos/injection group/replicate. (F) Number of red (photoconverted) lysosome C-labeled cells leaving the area of transection at 6 hpi over a time period of 3.5 hpc in phenol red- and dominant-active *hif-1α*-injected embryos at 2 dpf. Data shown are mean  $\pm$  SEM,  $n = 14$  performed as 3 independent experiments. Line of best fit shown is calculated by linear regression.  $P$  value shown is the difference between the 2 slopes. (G) Injection of *hif-1αb* with each hydroxylation site mutated individually shows that the asparagine hydroxylation site of Fih is not required for resolution of neutrophilic inflammation. Mutation of either proline hydroxylation site of Hif-1 $\alpha$  was sufficient to lead to the decrease in neutrophil inflammation resolution. Data shown are mean  $\pm$  SEM,  $n = 24$  performed as 2 independent experiments. (H) *Tg(lyz:Gal4)i252;Tg(UAS:da-hif-1αb-IRES-GFP)i218* positive embryos and wild-type siblings underwent tailfin transection at 3 dpf. Data shown are 24 hpi TSA-positive neutrophil counts, mean  $\pm$  SEM,  $n = 30$  performed as 3 independent experiments. (I) *Tg(lyz:Gal4)i252;Tg(UAS:da-hif-1αb-IRES-GFP)i218* positive embryos had a lower rate of neutrophil apoptosis analyzed by TUNEL staining at 12 hpi after tail transection at 3 dpf. Data shown are mean  $\pm$  SEM,  $n = 3$  performed as independent experiments containing 9 to 40 embryos/treatment group/replicate.

vitro studies have shown effects on neutrophil function and life span,<sup>14-16,19</sup> there has been no previous study of the effects of HIF signaling on neutrophil behavior during inflammation in vivo. We found recruitment of neutrophils to the injury site was unaffected by hydroxylase inhibition, and in addition, the pattern of neutrophil localization was unaltered in uninjured embryos. Neutrophil migration properties including speed and meandering of neutrophils during the recruitment phase also were not affected. DMOG did, however, cause a delay in the resolution of inflammation in association with an increase in HIF signaling. HIF signaling

pathways therefore modulate the resolution rather than recruitment phase of inflammation. The number of neutrophils at the transection site in DMOG-treated embryos had reached basal levels by 48 hpi, suggesting that the abrogation of hydroxylase activity delays rather than prevents the resolution of inflammation.

There are 2 plausible explanations for the decrease in inflammation resolution observed in DMOG-treated zebrafish embryos: neutrophils are actively retained at the site of injury or neutrophil apoptosis is suppressed. Movement of neutrophils away from sites of injury and infection, by reverse migration, has been reported



several zebrafish studies.<sup>8-10</sup> A similar phenomenon has been reported in some mammalian systems, although the underlying mechanisms are less well understood.<sup>7</sup> Cell tracking experiments were performed to assess movement of neutrophils away from the wound region. In DMOG-treated embryos, fewer labeled neutrophils left the site of transection over a 3.5-hour period during the resolution phase of inflammation, and neutrophils traveled a shorter distance away from the wound zone. These effects of DMOG were blocked by dominant-negative and replicated by dominant-active Hif constructs, indicating Hif signaling retained neutrophils in the wound zone during the resolution phase. By labeling a small population of cells at the injury site, we were able to show that the same number of neutrophils remains in the labeled region in DMOG-treated embryos in the resolution phase and that neutrophils migrate with the same speed and meandering index. The difference between these populations is purely a difference in the direction of the migrating neutrophils. Blocking hydroxylases led to more neutrophils patrolling the injury site rather than moving away from the injury site. This change in migration direction may reflect a differential response of neutrophils to existing chemotactic gradients, perhaps as a result of altered chemokine receptor expression.<sup>43</sup> It is unlikely that global activation of Hif signaling causes a change in the chemical gradients at the injury site, because neutrophil-specific expression of dominant Hif-1 $\alpha$  led to persisting inflammation. The decrease in reverse migration after Hif activation is probably responsible, in part, for the decrease in the resolution of neutrophilic inflammation. To our knowledge, this is the first report of the modulation of a genetic pathway directly altering the migratory behavior of neutrophils specifically during inflammation resolution. Whether this represents a global effect of HIF signaling on inflammation resolution, or whether it is specific to zebrafish, will require careful experimentation in emerging models of in vivo inflammation in mammalian systems.

In addition, DMOG treatment caused a modest but significant decrease in the levels of neutrophil apoptosis in the resolution phase of inflammation. This is also likely to contribute to the delay in resolution observed after hydroxylase inhibition. This effect was shown to be Hif-dependent because dominant-active Hif down-regulated apoptosis. Expressing dominant-active Hif specifically in neutrophils was able to decrease neutrophil apoptosis showing this effect is mediated by the neutrophils themselves. Up-regulated hypoxia has been demonstrated previously to decrease neutrophil apoptosis in mammalian systems<sup>14-16,19</sup>; however, this is the first time this effect has been observed in vivo in a whole organism. Dominant-negative Hif expression did not detectably increase apoptosis levels compared with controls. This probably indicates that levels of Hif are low during the normal process of inflammation resolution; therefore, further inhibition of this pathway does not significantly affect neutrophil apoptosis.

It is difficult to assess the relative contribution of apoptosis versus reverse migration to the clearance of neutrophils after Hif activation, because the number of apoptotic cells identified depends on unknown variables, such as the duration for which an apoptotic neutrophil can be detected before it is degraded after macrophage ingestion. However, these data suggest both apoptosis and reverse migration probably play an important role in the clearance of neutrophils.

Given the potential for nonspecific effects of competitive hydroxylase inhibition by DMOG, and the lack of selective inhibitors of individual PHD enzymes, there were multiple possible modes of action of DMOG in vivo. DMOG has targets other than the HIF hydroxylases and PHD enzymes themselves have HIF-

independent effects, including on the nuclear factor- $\kappa$ B pathway.<sup>44</sup> By manipulating gene expression, we have been able to establish a direct link between the effects of hydroxylase inhibition and Hif-1 $\alpha$ . Previous reports have shown that an *arnt-1* translation blocking morpholino is able to block Hif-1 $\alpha$  signaling.<sup>31</sup> We found that morpholino mediated knockdown of Arnt-1, an obligate binding partner of Hif-1 $\alpha$ , is able to block the delay in inflammation resolution caused by DMOG. In addition, we found that the proinflammatory effects of DMOG were replicated by dominant-active *hif-1 $\alpha$ b* and blocked by dominant-negative *hif-1 $\alpha$ b*. Dominant-active *hif-1 $\alpha$ b* delayed the resolution of inflammation to a similar degree to that of DMOG treatment alone. Interestingly, dominant-active *hif-1 $\alpha$ b* also increased the whole-body neutrophil number. This might be a feature of suppression of neutrophil apoptosis during hematopoiesis, or of an increase in myeloid cell production after hypoxic stimulation. This effect is not seen with either DMOG or hypoxia itself (supplemental Figure 1B; data not shown), but prolonged exposure of developing larvae to DMOG or to direct hypoxia is toxic to embryos (data not shown). This agrees with the findings in *vhl* mutants, in which increased Hif signaling leads to increased leukocyte number.<sup>42</sup> By developing a stable *UAS:da-hif-1 $\alpha$ b* transgenic line, we were able to drive the expression of *da-hif-1 $\alpha$ b* specifically in *lyz*-expressing leukocytes. We were able to demonstrate that overactivation of the Hif-1 $\alpha$  pathway in neutrophils alone was able to induce the delay in the resolution of neutrophilic inflammation observed when Hif-1 $\alpha$  was up-regulated across all tissues of the embryo.

The 2 zebrafish homologs of human HIF-1 $\alpha$  had different effects on neutrophilic inflammation. Hif-1 $\alpha$ b was able to modulate the resolution of neutrophilic inflammation: dominant-active Hif-1 $\alpha$ b was able to replicate the effect of hydroxylase inhibition, whereas dominant-negative Hif-1 $\alpha$ b almost completely blocked the DMOG effect. This is consistent with Hif-1 $\alpha$ b being the hypoxia transcription factor responsible for the timely resolution of neutrophilic inflammation. Hif-1 $\alpha$ a, by contrast, had no significant effect on neutrophil behavior in the assays we performed. Interestingly, Hif-1 $\alpha$ a has less sequence homology to human of HIF-1 $\alpha$  than Hif-1 $\alpha$ b.<sup>45</sup> In particular, Hif-1 $\alpha$ a lacks the first conserved proline site for Phd hydroxylation, although it does have the second conserved proline site, and the Fih asparagine. The loss of complete Phd hydroxylation in Hif-1 $\alpha$ a may indicate a divergence of the role of Hif-1 $\alpha$ a in evolution away from a role in transducing the hypoxic signal in inflammatory cells.

To assess the role of hydroxylation at different sites in Hif-1 $\alpha$ , we assayed inflammation resolution in zebrafish larvae injected with a range of dominant Hif-1 $\alpha$ b constructs, in which Phd and Fih hydroxylation sites were mutated alone and in combination. Mutation of either Phd hydroxylation site reproduced the delay of inflammation resolution phenotype, consistent with a stabilization of Hif, suggesting that either site may function independently, in keeping with the recent in vitro crystal structure of hydroxyproline recognition by pVHL.<sup>46</sup> These data are consistent with Phd hydroxylation of Hif-1 $\alpha$ b being required for the timely resolution of neutrophilic inflammation. Although in vitro FIH/HIF interaction has been proposed to partially determine oxygen sensitivity, mutation of the Fih hydroxylation site, either alone or in combination with mutation of the Phd sites, had no detectable effect on inflammation resolution. This suggests that in zebrafish neutrophils, Phd enzymes are the critical regulators of Hif activity.

Our data show that Hif-1 $\alpha$  delays the resolution of inflammation in a whole-organism in vivo model. We show for the first time that this delay in resolution is caused by suppression of the

movement of neutrophils away from the site of inflammation in favor of patrolling the inflamed area, and by a decrease in neutrophil apoptosis. Furthermore, we find that hydroxylation of Hif-1 $\alpha$  by Phd enzymes is required for the timely resolution of neutrophilic inflammation. By developing the stable *UAS:da-hif-1 $\alpha$ b* transgenic line, we are able to show that this depends on Hif signaling within the neutrophil. These data have important implications in understanding the role of HIF-hydroxylase signaling in innate immune responses and, in addition, provide an illustration of how zebrafish models might elucidate key regulators of inflammatory signaling pathways with relevance to human health.

## Acknowledgments

The authors thank Catherine Loynes for assistance in establishing the techniques used in this study.

This work was funded by a project grant from the Wellcome Trust (WT082909MA), an MRC Senior Clinical Fellowship (G0701932; S.A.R.) and by A\*STAR (Singapore). S.R.W. holds a Wellcome Intermediate Fellowship (WT078244AIA). Microscopy studies were supported by a Wellcome Trust grant to the Molecular

Biology and Biotechnology/Biomedical Science Light Microscopy Facility (GR077544AIA), and the work was supported by an MRC Center grant (G0700091).

## Authorship

Contribution: F.J.v.E., S.R.W., M.K.B.W., and S.A.R. conceived the study and designed the experiments with P.M.E.; P.W.I. and X.W. generated new transgenic reagents; P.M.E., F.J.v.E., P.W.I., M.K.B.W., S.R.W., and S.A.R. wrote the manuscript; C.C.R.-A. assisted and advised on image processing; and P.M.E. and G.D. performed the experiments.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for C.C.R.-A. is Biomedical Engineering Research Group, School of Engineering and Design, University of Sussex, Brighton, United Kingdom.

Correspondence: Stephen A. Renshaw, MRC Centre for Developmental and Biomedical Genetics, University of Sheffield, Western Bank, Sheffield, S10 2TN, United Kingdom; e-mail: s.a.renshaw@sheffield.ac.uk.

## References

- Barton GM. A calculated response: control of inflammation by the innate immune system. *J Clin Invest*. 2008;118(2):413-420.
- Haslett C. Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. *Clin Sci (Lond)*. 1992;83(6):639-648.
- Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. *J Clin Invest*. 1989;83(3):865-875.
- Cox G, Crossley J, Xing Z. Macrophage engulfment of apoptotic neutrophils contributes to the resolution of acute pulmonary inflammation in vivo. *Am J Respir Cell Mol Biol*. 1995;12(2):232-237.
- Grigg JM, Savill JS, Sarraf C, Haslett C, Silverman M. Neutrophil apoptosis and clearance from neonatal lungs. *Lancet*. 1991;338(8769):720-722.
- Uller L, Persson CG, Erjefalt JS. Resolution of airway disease: removal of inflammatory cells through apoptosis, egression or both? *Trends Pharmacol Sci*. 2006;27(9):461-466.
- Buckley CD, Ross EA, McGettrick HM, et al. Identification of a phenotypically and functionally distinct population of long-lived neutrophils in a model of reverse endothelial migration. *J Leukoc Biol*. 2006;79(2):303-311.
- Mathias JR, Perrin BJ, Liu TX, Kanki J, Look AT, Huttenlocher A. Resolution of inflammation by retrograde chemotaxis of neutrophils in transgenic zebrafish. *J Leukoc Biol*. 2006;80(6):1281-1288.
- Brown SB, Tucker CS, Ford C, Lee Y, Dunbar DR, Mullins JJ. Class III antiarrhythmic methanesulfonanilides inhibit leukocyte recruitment in zebrafish. *J Leukoc Biol*. 2007;82(1):79-84.
- Hall C, Flores MV, Storm T, Crosier K, Crosier P. The zebrafish lysozyme C promoter drives myeloid-specific expression in transgenic fish. *BMC Dev Biol*. 2007;7:42.
- Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. *J Leukoc Biol*. 1993;54(4):283-288.
- Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. *Blood*. 1992;80(8):2012-2020.
- Sabroe I, Dower SK, Whyte MK. The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis. *Clin Infect Dis*. 2005;41(suppl 7):S421-S426.
- Hannah S, Mecklenburgh K, Rahman I, et al. Hypoxia prolongs neutrophil survival in vitro. *FEBS Lett*. 1995;372(2-3):233-237.
- Mecklenburgh KI, Walmsley SR, Cowburn AS, et al. Involvement of a ferroprotein sensor in hypoxia-mediated inhibition of neutrophil apoptosis. *Blood*. 2002;100(8):3008-3016.
- Walmsley SR, Print C, Farahi N, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1 $\alpha$ -dependent NF- $\kappa$ B activity. *J Exp Med*. 2005;201(1):105-115.
- Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1 $\alpha$  is essential for myeloid cell-mediated inflammation. *Cell*. 2003;112(5):645-657.
- Peyssonnaud C, Datta V, Cramer T, et al. HIF-1 $\alpha$  expression regulates the bactericidal capacity of phagocytes. *J Clin Invest*. 2005;115(7):1806-1815.
- Walmsley SR, Cowburn AS, Clatworthy MR, et al. Neutrophils from patients with heterozygous germline mutations in the von Hippel Lindau protein (pVHL) display delayed apoptosis and enhanced bacterial phagocytosis. *Blood*. 2006;108(9):3176-3178.
- Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. *Cell*. 2001;107(1):43-54.
- Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. *Science*. 2001;294(5545):1337-1340.
- Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. *Mol Cell*. 2008;30(4):393-402.
- Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Mol Cell Biol*. 1992;12(12):5447-5454.
- Wenger RH. Cellular adaptation to hypoxia: O<sub>2</sub>-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O<sub>2</sub>-regulated gene expression. *FASEB J*. 2002;16(10):1151-1162.
- Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF- $\alpha$  to the von Hippel-Lindau ubiquitylation complex by O<sub>2</sub>-regulated prolyl hydroxylation. *Science*. 2001;292(5516):468-472.
- Renshaw SA, Loynes CA, Trushell DM, Elworthy S, Ingham PW, Whyte MK. A transgenic zebrafish model of neutrophilic inflammation. *Blood*. 2006;108(13):3976-3978.
- Nusslein-Volhard C. *Zebrafish: a Practical Approach*. 1st ed. Oxford: Oxford University Press; 2002.
- Loynes CA, Martin JS, Robertson A, et al. Pivotal advance: pharmacological manipulation of inflammation resolution during spontaneously resolving tissue neutrophilia in the zebrafish. *J Leukoc Biol*. 2010;87(2):203-212.
- Sidi S, Sanda T, Kennedy RD, et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. *Cell*. 2008;133(5):864-877.
- Kwan KM, Fujimoto E, Grabher C, et al. The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. *Dev Dyn*. 2007;236(11):3088-3099.
- Prasch AL, Tanguay RL, Mehta V, Heideman W, Peterson RE. Identification of zebrafish ARNT1 homologs: 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in the developing zebrafish requires ARNT1. *Mol Pharmacol*. 2006;69(3):776-787.
- Manotham K, Tanaka T, Ohse T, et al. A biologic role of HIF-1 in the renal medulla. *Kidney Int*. 2005;67(4):1428-1439.
- Chan DA, Sutphin PD, Yen SE, Giaccia AJ. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 $\alpha$ . *Mol Cell Biol*. 2005;25(15):6415-6426.
- Linke S, Stojkoski C, Kewley RJ, Booker GW, Whitelaw ML, Peet DJ. Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor-inhibiting hypoxia-inducible factor. *J Biol Chem*. 2004;279(14):14391-14397.
- Krauss S, Concordet JP, Ingham PW. A functionally conserved homolog of the *Drosophila* segment polarity gene hh is expressed in tissues with polarizing activity in zebrafish embryos. *Cell*. 1993;75(7):1431-1444.
- Thisse C, Thisse B. High-resolution in situ hybridization to whole-mount zebrafish embryos. *Nat Protoc*. 2008;3(1):59-69.
- Gray CA, Loynes CA, Whyte MK, Crossman DC,

- Renshaw SA, Chico TJ. Simultaneous intravital imaging of macrophage and neutrophil behaviour during inflammation using a novel transgenic zebrafish. *Thrombosis Haemostasis*. 2011; 105(5): 811–819.
38. Le Guyader D, Redd MJ, Colucci-Guyon E, et al. Origins and unconventional behavior of neutrophils in developing zebrafish. *Blood*. 2008;111(1): 132–141.
  39. Howie SE, Harrison DJ, Wyllie AH. Lymphocyte apoptosis-mechanisms and implications in disease. *Immunol Rev*. 1994;142:141–156.
  40. Ando R, Hama H, Yamamoto-Hino M, Mizuno H, Miyawaki A. An optical marker based on the UV-induced green-to-red photoconversion of a fluorescent protein. *Proc Natl Acad Sci U S A*. 2002; 99(20):12651–12656.
  41. Lieschke GJ, Oates AC, Crowhurst MO, Ward AC, Layton JE. Morphologic and functional characterization of granulocytes and macrophages in embryonic and adult zebrafish. *Blood*. 2001;98(10): 3087–3096.
  42. van Rooijen E, Voest EE, Logister I, et al. Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia. *Blood*. 2009;113(25):6449–6460.
  43. Weisel KC, Bautz F, Seitz G, Yildirim S, Kanz L, Mohle R. Modulation of CXC chemokine receptor expression and function in human neutrophils during aging in vitro suggests a role in their clearance from circulation. *Mediators Inflamm*. 2009; 2009:790174.
  44. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates I $\kappa$ B kinase- $\beta$ , giving insight into hypoxia-induced NF $\kappa$ B activity. *Proc Natl Acad Sci U S A*. 2006;103(48):18154–18159.
  45. Rojas DA, Perez-Munizaga DA, Centanin L, et al. Cloning of hif-1 $\alpha$  and hif-2 $\alpha$  and mRNA expression pattern during development in zebrafish. *Gene Expr Patterns*. 2007;7(3): 339–345.
  46. Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1  $\alpha$  by pVHL. *Nature*. 2002;417(6892): 975–978.